Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Clinical trial NCT04305041 · COMPLETED
Trial details
- NCT number
- NCT04305041
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-26
- Primary completion
- 2025-08-25
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.